- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 413/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Patent holdings for IPC class C07D 413/02
Total number of patents in this class: 204
10-year publication summary
|
14
|
15
|
8
|
12
|
11
|
5
|
10
|
9
|
16
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2183 |
8 |
| Boehringer Ingelheim International GmbH | 4491 |
7 |
| Centrexion Therapeutics Corporation | 65 |
6 |
| Epizyme, Inc. | 360 |
5 |
| Genentech, Inc. | 4157 |
4 |
| Syngenta Crop Protection AG | 6804 |
3 |
| Abbvie Inc. | 1812 |
3 |
| MEI Pharma, Inc. | 42 |
3 |
| Merck Sharp & Dohme LLC | 3734 |
3 |
| Bristol-myers Squibb Company | 4747 |
2 |
| F. Hoffmann-La Roche AG | 7795 |
2 |
| Merck Patent GmbH | 5751 |
2 |
| Bayer HealthCare LLC | 1301 |
2 |
| Alexion Pharmaceuticals, Inc. | 650 |
2 |
| Alkahest, Inc. | 97 |
2 |
| Astex Therapeutics Limited | 206 |
2 |
| Cancer Research Technology Limited | 517 |
2 |
| Celgene Corporation | 1408 |
2 |
| Galera Labs, LLC | 28 |
2 |
| The Global Alliance for TB Drug Development, Inc. | 42 |
2 |
| Other owners | 140 |